Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
Observational long-term follow-up (planned 15 years) of males with Fabry disease who received the lentiviral gene-modified autologous cell therapy AVR-RD-01 in study AVRO-RD-01-201. Terminated by the sponsor for business reasons after 5 participants; no results were posted or published.
| Status | Terminated |
|---|---|
| Primary Endpoint Result | Not Reported |
| Enrollment | 5 |
| Start Date | 2019-05-08 |
| Primary Completion Date | 2023-08-16 |
Why Stopped
This study was voluntarily terminated due to a business decision not to proceed, and not due to any safety or efficacy issue.
Results Summary
No results have been posted to ClinicalTrials.gov and the registry lists no publications for this study, so no outcome data are available. The study enrolled 5 participants (actual) at 3 sites in Australia and Brazil, and was terminated on 2023-08-16 by a sponsor business decision. The registry states the termination was not due to any safety or efficacy issue. None of the 6 registered primary safety outcomes or 9 secondary outcomes has been reported.
Design Implications
The study reported no data, so it gives no efficacy or safety lesson for AVR-RD-01 or for lentiviral hematopoietic stem cell gene therapy in Fabry disease. Its design shows what regulators and sponsors expect to monitor after lentiviral vector integration: replication-competent lentivirus, integration site analysis for clonal expansion, and anti-enzyme antibodies, alongside enzyme activity, vector copy number, Gb3, eGFR and left ventricular mass index for up to 15 years. A small rare-disease cohort followed by a separate long-term study is vulnerable to sponsor withdrawal, which ends follow-up before durability data exist. Plan follow-up commitments so that it survives a program stop.
Rationale
AVR-RD-01 is autologous hematopoietic stem cells modified ex vivo with a lentiviral vector, given once in the parent study AVRO-RD-01-201 to men with Fabry disease. Fabry disease is caused by deficient alpha-galactosidase A (AGA, encoded by GLA), which leads to Gb3 accumulation in tissues. Engrafted gene-modified cells were expected to supply AGA enzyme for years. Because lentiviral vectors integrate into the genome, this study monitors safety (replication-competent lentivirus, aberrant clonal expansion by integration site analysis, anti-AGA antibodies) and durability (AGA activity, vector copy number, Gb3, kidney and heart measures) for up to 15 years. No investigational product is given in this study.
Limitations
Terminated after 5 participants with no posted or published results, so no safety, durability or efficacy conclusion can be drawn. It is observational and single-arm, with no comparator, and it enrolled only males aged 16 to 50 years. The termination reason is a business decision, not a scientific finding.
Registry record
This is a multinational, long-term follow-up study to assess the long-term safety and durability of AVR-RD-01 treatment in participants who received a single dose administration of lentiviral gene therapy in Study AVRO-RD-01-201 (treatment study). No investigational product will be administered in this study. Participants will continue periodic safety and efficacy assessments in this long-term follow-up study up to 15 years from AVR-RD-01 gene therapy infusion.
| Primary Outcomes | Incidence of clinically significant AEs and SAEs, Number of participants with clinically relevant abnormalities, as assessed by clinical laboratory tests, Number of participants with clinically relevant abnormalities, as assessed by vital signs, Presence of anti-Alpha-galactosidase A (AGA) antibodies, Presence of replication competent lentivirus (RCL), Evaluate for the presence of aberrant clonal expansion as assessed by integration site analysis (ISA) |
|---|---|
| Keywords | Fabry Disease, Cell therapy, Gene therapy, Long-term follow-up, Lysosomal storage disorder, Lenti-viral |
| Registry Last Updated | 2023-08-31 |
| Minimum Age | 16 Years |
| Modalities | gene_therapy, cell_therapy |
| Maximum Age | 50 Years |
| Intervention Names | Safety and Efficacy Assessments, Gene Therapy Intervention |
| Has Results | No |
| Enrollment Type | Actual |
| Countries | Australia, Brazil |
| Intervention Types | other |
| Study Type | Observational |
| Healthy Volunteers | No |
| Condition Terms | Fabry Disease, Lysosomal Storage Diseases |
| Completion Date | 2023-08-16 |
| Lead Sponsor Class | Industry |
| Eligibility Sex | Male |
| Stop Reason Category | Business |
Official Title
A Long-Term Follow-Up Study of Subjects With Fabry Disease Who Previously Received Ex-Vivo, Lentiviral Vector-Mediated Gene-Modified Autologous Cell Therapy AVR-RD-01 in Study AVRO-RD-01-201
Eligibility Criteria
Inclusion Criteria:
1. Subject must have been enrolled and received AVR-RD-01 in the AVRO-RD-01-201 study.
Exclusion Criteria:
-
Subject has any medical, psychological, or other condition that, in the opinion of the Investigator:
- Might interfere with the subject's participation in the study (including consenting to procedures); and/or
- Poses any additional risk to the subject; and/or
- Might confound the results of any study-required assessments.
-
Subject is currently enrolled in an AVROBIO-sponsored AVR-RD-01 treatment study.
Identifiers & revision
clinicaltrials NCT04999059
